Inactive

Under the U.S. Government’s (USG) COVID-19 Response mission, HHS is leading a whole of nation effort with the primary goal to execute on a well-defined portfolio of COVID-19 medical countermeasure (MC... Under the U.S. Government’s (USG) COVID-19 Response mission, HHS is leading a whole of nation effort with the primary goal to execute on a well-defined portfolio of COVID-19 medical countermeasure (MCM) candidates to maximize availability of safe and effective vaccines, therapeutics and diagnostics as fast as possible for mass distribution. As such, BARDA has a specific need to procure orally administered, direct-acting antiviral therapeutic treatment. W911QY-20-S-C001 AoI 05 COVID-19 Oral Antiviral amended on 13 Sep 2021 Amendment 1 W911QY-20-S-C001 AoI 05 Oral Antiviral amended on 6 Jul 2021